AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Guardian3 Aug 2026Macro
Automatically composed with AI from the cited sources

No desk note for this article — the source text is below.

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling